Ovarian Reserve Profile- Basic (FSH, E2, AMH)

The Ovarian Reserve Profile – Basic is a combined blood-test panel that measures Follicle-Stimulating Hormone (FSH), estradiol (E2) and Anti-Müllerian Hormone (AMH). These hormones provide complementary information about the remaining ovarian follicle pool, current ovarian activity and the communication between the pituitary gland and ovaries.

Ovarian reserve refers to the number of eggs remaining in the ovaries at a particular time. It naturally decreases with age, but the rate of decline differs between individuals. Ovarian reserve testing may help fertility specialists estimate how the ovaries are likely to respond to stimulation during fertility treatment. It cannot directly determine egg quality or guarantee whether natural pregnancy will occur.

AMH is produced by cells surrounding small developing follicles in the ovaries. FSH is released by the pituitary gland and stimulates ovarian follicles to develop. Estradiol is an estrogen produced mainly by growing ovarian follicles. Because these three markers reflect different aspects of ovarian function, doctors often interpret them together rather than relying on a single value.

Benefits of the Test

• Evaluates three important hormones associated with ovarian reserve and function.
• Provides an estimate of the remaining ovarian follicle pool through AMH measurement.
• Assesses pituitary stimulation of the ovaries through FSH measurement.
• Measures estradiol to help interpret early-cycle ovarian activity.
• Supports fertility assessment and assisted-reproduction planning.
• May help identify a pattern consistent with reduced ovarian reserve.
• Provides baseline results for monitoring selected fertility treatments.
• May support counselling before egg freezing or fertility preservation.

Why Doctors Recommend This Test

A doctor may recommend this profile when a woman is experiencing difficulty becoming pregnant, considering fertility treatment or seeking information about ovarian reserve. Testing may also be appropriate before egg freezing, in-vitro fertilisation or another assisted-reproductive procedure.

The panel may be advised for women with irregular or absent menstrual periods, a family history of early menopause, previous ovarian surgery, endometriosis or medical treatment that may affect ovarian function. Chemotherapy and radiation involving the pelvic region can reduce ovarian reserve in some patients.

AMH is commonly used to estimate the number of developing follicles and predict the likely ovarian response to fertility medicines. A lower-than-expected AMH level may suggest reduced ovarian reserve. A higher level may indicate a larger follicle pool and can also occur in women with polycystic ovary syndrome. AMH alone cannot diagnose PCOS or infertility.

FSH stimulates follicle development during the first part of the menstrual cycle. When the ovaries respond less effectively, the pituitary gland may release more FSH. Therefore, a persistently elevated early-cycle FSH result may be associated with reduced ovarian reserve. FSH can vary between menstrual cycles and should not be interpreted from one result without clinical context.

Estradiol is measured with FSH because an elevated early-cycle estradiol level may suppress FSH and make the FSH result appear lower than expected. Evaluating both markers together can provide a more complete picture of early-cycle ovarian activity.

Preparation Before Test

Fasting is generally not required for the Ovarian Reserve Profile – Basic. However, follow any specific instructions provided by the doctor or laboratory. A healthcare professional will collect a blood sample from a vein, usually in the arm.

FSH and estradiol are commonly measured during the early follicular phase, often on day 2 or day 3 of the menstrual cycle. Day 1 is generally considered the first day of full menstrual bleeding. The treating doctor should determine the correct collection day because testing requirements may vary according to menstrual pattern and clinical purpose.

AMH usually varies less during the menstrual cycle than FSH and estradiol and can often be measured on any cycle day. When AMH is included with early-cycle FSH and E2, the complete panel is generally collected according to the timing required for FSH and estradiol.

Inform the doctor about hormonal contraceptives, fertility medicines, estrogen therapy, pregnancy, breastfeeding and all prescribed or non-prescribed medicines. These factors may influence hormone concentrations or their interpretation. Do not stop any prescribed medicine without medical advice.

Provide the date of the last menstrual period, average cycle length and information about irregular bleeding, ovarian surgery, pregnancy or current fertility treatment. These details help the doctor interpret the results appropriately.

Normal Reporting Time

The Ovarian Reserve Profile – Basic report is commonly available within 24–48 hours after the laboratory receives a suitable blood sample. Individual components may be processed at different times. Reporting time can vary according to collection time, analytical schedule, quality-control requirements and result verification.

Who Should Take This Test?

This profile may be appropriate for women experiencing difficulty conceiving, planning fertility treatment, considering egg freezing or seeking medical assessment of possible reduced ovarian reserve. It may also be requested before ovarian-stimulation treatment to help determine the expected response.

Doctors may recommend testing for women with irregular or absent periods, early menopausal symptoms, previous ovarian surgery, endometriosis, autoimmune conditions affecting ovarian function or a family history of premature menopause.

The profile should be performed according to medical advice. It is not a universal fertility screening test and cannot independently predict the time available to become pregnant. Age remains an important factor because egg quality and pregnancy potential generally decline with increasing reproductive age.

Detailed Information

AMH is produced by granulosa cells in pre-antral and small antral follicles. Its concentration generally decreases as the ovarian follicle pool becomes smaller. AMH is useful for estimating ovarian response during fertility treatment, but no AMH value can establish that conception is impossible or certain.

FSH is produced by the anterior pituitary gland. At the beginning of the menstrual cycle, it stimulates several ovarian follicles to develop. As follicles grow, they produce estradiol, which provides feedback to the pituitary gland. This feedback relationship is why FSH and estradiol should be evaluated together.

Estradiol is the main circulating estrogen during the reproductive years. It supports follicle development and growth of the uterine lining. E2 levels change substantially throughout the menstrual cycle, so the collection day is essential for meaningful interpretation.

A pattern of low AMH, elevated early-cycle FSH and an altered estradiol result may support a diagnosis of diminished ovarian reserve, but no single pattern applies to every patient. Results can vary because of age, menstrual timing, hormonal medicines, laboratory methods and individual biology.

A higher AMH level may occur in women with a larger number of follicles or PCOS. It does not necessarily mean that fertility is better. Similarly, a normal AMH value does not evaluate fallopian-tube openness, uterine health, sperm quality, fertilisation or embryo development.

Ovarian reserve testing may be interpreted with an antral follicle count performed by pelvic ultrasound. Depending on the clinical history, additional evaluation may include LH, prolactin, TSH, progesterone, tubal-patency testing and semen analysis of the male partner.

Reference intervals vary according to age, menstrual-cycle phase, analytical method and laboratory. Results should be interpreted using the ranges printed on the report and reviewed by a gynaecologist or fertility specialist together with reproductive history and ultrasound findings.